Imugene Reports Positive Response Rates in Azer-Cel Phase 1b Study

Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company developing immunotherapies, has announced promising results from its Phase 1b study of azer-cel, an off-the-shelf, allogeneic CAR T ...

$7.25B settlement over Roundup weed killers: Who qualifies, and how much you could receive

A $7.25 billion class action settlement meant to resolve claims that Monsanto’s Roundup products caused cancer in people has received preliminary approval from a Missouri court, lawyers confirmed on ...
The American Journal of Managed Care

Predicting Infection Risk in CLL Using Domain Adaptation

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
Healio

Guidelines provide ‘vital standardization’ of treatment for AYAs with acute leukemia

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...